Emerging drugs for the treatment of bladder storage dysfunction

Forskningsoutput: TidskriftsbidragÖversiktsartikelPeer review

Sammanfattning

Introduction: Current drug treatment of lower urinary tract disorders, for example, overactive bladder syndrome and lower urinary tract symptoms associated with benign prostatic hyperplasia, is moderately effective, has a low treatment persistence and some short- and long-term adverse events. Even if combination therapy with approved drugs may offer advantages in some patients, there is still a need for new agents. Areas covered: New b3-adrenoceptor agonists, antimuscarinics, the naked Maxi-K channel gene, a novel 5HT/NA reuptake inhibitor and soluble guanylate cyclase activators are discussed. Focus is given to P2X3 receptor antagonists, small molecule blockers of TRP channels, the roles of cannabis on incontinence in patients with multiple sclerosis, and of drugs acting directly on CB1 and CB2 receptor or indirectly via endocannabinoids by inhibition of fatty acid aminohydrolase. Expert opinion: New potential alternatives to currently used drugs/drug principles are emerging, but further clinical testing is required before they can be evaluated as therapeutic alternatives. It seems that for the near future individualized treatment with approved drugs and their combinations will be the prevailing therapeutic approach.

Originalspråkengelska
Sidor (från-till)277-287
Antal sidor11
TidskriftExpert Opinion on Emerging Drugs
Volym27
Nummer3
Tidigt onlinedatum2022
DOI
StatusPublished - 2022

Bibliografisk information

Publisher Copyright:
© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

Ämnesklassifikation (UKÄ)

  • Farmakologi och toxikologi

Fingeravtryck

Utforska forskningsämnen för ”Emerging drugs for the treatment of bladder storage dysfunction”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här